Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 23, 2026
TickeronGET DAILY SIGNALS
Why Is QuidelOrtho (QDEL) Stock Down -6.01% Today?

Why Is QuidelOrtho (QDEL) Stock Down -6.01% Today?

Key Takeaways

  • QuidelOrtho shares fell 6.01%, dropping $0.81 to $12.67 from a prior close of $13.48.
  • The decline extends a volatile stretch driven by persistent China demand weakness, muted respiratory-testing demand, and a steep full-year guidance cut.
  • Secondary pressure comes from balance-sheet concerns, including roughly $2.8 billion in net debt and negative cash generation.
  • The move diverges from a steadier broader market, reflecting stock-specific fundamental and sentiment headwinds rather than a broad sector rotation.
  • Traders are watching the company's third-quarter earnings report scheduled for November 3, 2026, as the next key catalyst.
  • For deeper data on Price Targets, Earnings, and Forecast for QDEL, explore the dedicated analysis pages.
  • Explore Trending AI Robots to see which AI trading strategies are currently outperforming in this environment.

Opening Summary

QuidelOrtho Corporation (QDEL), a global provider of in-vitro diagnostic solutions spanning clinical chemistry, immunoassay, immunohematology, and molecular testing, saw its shares fall sharply in Friday's session. The stock declined 6.01%, or $0.81, to trade at $12.67 versus a prior closing price of $13.48. The sell-off marks a continuation of recent volatility for the diagnostics maker, with markets attributing the move to lingering concerns around China-related purchasing disruptions, softer respiratory-testing demand, and the company's recently lowered financial outlook.

China Demand and Respiratory Headwinds Weigh on Sentiment

The primary overhang on QDEL remains weakness in its China business, where distributor purchasing has slowed following shifts in pricing guidance from the country's National Healthcare Security Administration. Management has signaled that these China-related challenges are expected to persist through the back half of the year. At the same time, respiratory-testing demand — a historically high-margin but variable revenue stream — has continued to underwhelm, with U.S. positivity rates and Southern Hemisphere flu-season data tracking below prior-year levels. Both factors directly pressure revenue and margins in the near term.

Full-Year Guidance Cut and Balance-Sheet Concerns

Investors are also contending with a meaningful downward revision to the company's full-year 2026 guidance. Management lowered its revenue outlook to a range of $2.52 billion to $2.60 billion and slashed adjusted EPS guidance to $0.65 to $0.90, while withdrawing free cash flow guidance altogether amid uncertainty in China and around respiratory-season strength. The company carries roughly $2.8 billion in net debt, largely from its 2022 acquisition of Ortho Clinical Diagnostics, which has amplified scrutiny of its cash generation and deleveraging path. These leverage and profitability concerns have kept a lid on the stock even as core laboratory and immunohematology franchises outside China remain relatively stable.

Market Context and Trading Activity

The decline in QDEL reflects stock-specific pressure rather than a broad healthcare-sector move, with the name trading independently of steadier major indices. The shares remain well below their 50-day and 200-day moving averages, and the session's move pushed the stock deeper below recently reclaimed levels near $14, underscoring weak technical positioning. Analyst sentiment has stayed cautious, with a consensus tilt toward "Reduce"/"Hold" ratings and a comparatively low average price target, reflecting diminished expectations for near-term earnings recovery.

What Comes Next for QDEL

The next decisive event for QDEL is its third-quarter 2026 earnings release, scheduled for after the market close on November 3, 2026. Investors will focus on China revenue trends, respiratory-season demand signals heading into the winter months, progress on the company's cost-optimization program, and any updates on cash flow and leverage reduction. Ongoing uncertainties include the durability of China headwinds, the trajectory of respiratory positivity rates, and the potential for strategic portfolio actions as the company works to strengthen its balance sheet. These factors leave the stock exposed to further volatility in the weeks ahead.

Trending AI Robots

Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots from a broader platform that offers hundreds of automated strategies covering thousands of tickers. Only the strongest performers under current market conditions are featured, with bots differing by strategy, timeframe, performance metrics, and the symbols they trade. For traders seeking data-driven approaches to navigating volatile names, this section provides a useful starting point to explore.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: QDEL

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


Momentum Indicator for QDEL turns negative, indicating new downward trend

QDEL saw its Momentum Indicator move below the 0 level on November 05, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 84 similar instances where the indicator turned negative. In 72 of the 84 cases, the stock moved further down in the following days. The odds of a decline are at 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for QDEL turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 41 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.

QDEL moved below its 50-day moving average on November 06, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for QDEL crossed bearishly below the 50-day moving average on November 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where QDEL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +2.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where QDEL advanced for three days, in 176 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.

QDEL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 99 of 151 cases where QDEL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 66%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.413) is normal, around the industry mean (4.142). P/E Ratio (-0.693) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.274) is also within normal values, averaging (40.124).

The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. QDEL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QDEL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -11%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -18%. MXCT experienced the highest price growth at 15%, while CODX experienced the biggest fall at -50%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -35%. For the same stocks of the Industry, the average monthly volume growth was -2% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 64
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 16 (-100 ... +100)
AI Patterns 1
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of diagnostic healthcare solutions

Industry MedicalNursingServices

Industry
Medical Specialties
Address
9975 Summers Ridge Road
Phone
+1 858 552-1100
Employees
6500
Web
https://www.quidelortho.com
Interact to see
Advertisement
Alphabet Inc. (GOOG) , the parent of Google, YouTube, and Google Cloud, is a common stock, not an exchange-traded fund. The central target of $400 is the arithmetic mean of current analyst price targets, which span a wide band from roughly $300 to $500, with the broad average near $397.
AAPL has shown stronger relative performance in recent weeks, holding near record highs while many artificial intelligence (AI)-focused tech stocks sold off. MSFT has lagged the market and now trades below its 50-day moving average amid concerns over heavy AI infrastructure spending.
Bending Spoons reported third-quarter 2026 revenue of $780.22 million, up 125.1% year over year and above the roughly $745.86 million consensus estimate. Earnings per share (EPS) came in at $0.42, beating the $0.26 consensus estimate by $0.16.
GOOG declined roughly 20% over the past 30 days, falling from about $331 to around $264 per share. The sell-off was triggered by Alphabet's third-quarter 2026 report, which revealed slowing Search advertising growth and an earnings miss.
Intel Corporation has delivered dramatically stronger relative price momentum over the past year, while SPY offers broad, diversified market exposure with far lower single-stock volatility. INTC's rally has been driven by a strategic turnaround under new leadership, backed by multi-billion-dollar investments from Nvidia, SoftBank, and the U.S. government.